Javier Martinez-Picado

Dr. Javier Martinez-Picado

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2007 in Science
Verified
Journal Article
Closed access
PDF file
JFJacques Fellay
Jacques Fellay
KSKevin V. Shianna
Kevin V. Shianna
DGDongliang Ge
Dongliang Ge
SCSara Colombo
Sara Colombo
BLBruno Ledergerber
Bruno Ledergerber
DGDavid B. Goldstein
David B. Goldstein
Understanding why some people establish and maintain effective control of HIV-1 and others do not is a priority in the effort to develop new treatments for HIV/AIDS. Using a whole-genome association strategy, we identified polymorphisms that explain nearly 15% of the variation among individuals in viral load during the asymptomatic set-point period of infection. One of these is found within an endogenous retroviral element and is associated with major histocompatibility allele human leukocyte antigen ( HLA )– B*5701 , whereas a second is located near the HLA-C gene. An additional analysis of the time to HIV disease progression implicated two genes, one of which encodes an RNA polymerase I subunit. These findings emphasize the importance of studying human genetic variation as a guide to combating infectious agents.

8 February 2004 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ALA J Leslie
A J Leslie
KPK J Pfafferott
K J Pfafferott
PCP Chetty
P Chetty
RDR Draenert
R Draenert
MAMarylyn M. Addo
Marylyn M. Addo
PGP J R Goulder
P J R Goulder

5 March 2019 in Nature
Verified
Journal Article
Closed access
PDF file
RGRavindra Gupta
Ravindra Gupta
SASultan Abdul-Jawad
Sultan Abdul-Jawad
LMLaura E. McCoy
Laura E. McCoy
HMHoi Ping Mok
Hoi Ping Mok
DPDimitra Peppa
Dimitra Peppa
EOEduardo Olavarria
Eduardo Olavarria

14 March 2010 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MBMaria Jose Buzon
Maria Jose Buzon
Marta MassanellaMarta Massanella
Marta Massanella
JLJosep M Llibre
Josep M Llibre
AEAnna Esteve
Anna Esteve
VDViktor Dahl
Viktor Dahl
JMJavier Martinez-Picado
Javier Martinez-Picado

1 April 2006 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
JMJavier Martinez-Picado
Javier Martinez-Picado
JPJulia G. Prado
Julia G. Prado
EFElizabeth Fry
Elizabeth Fry
KPKatja Pfafferott
Katja Pfafferott
ALAlasdair Leslie
Alasdair Leslie
PGPhilip Goulder
Philip Goulder
Mutational escape by human immunodeficiency virus (HIV) from cytotoxic T-lymphocyte (CTL) recognition is a major challenge for vaccine design. However, recent studies suggest that CTL escape may carry a sufficient cost to viral replicative capacity to facilitate subsequent immune control of a now attenuated virus. In order to examine how limitations can be imposed on viral escape, the epitope TSTLQEQIGW (TW10 [Gag residues 240 to 249]), presented by two HLA alleles associated with effective control of HIV, HLA-B*57 and -B*5801, was investigated. The in vitro experiments described here demonstrate that the dominant TW10 escape mutation, T242N, reduces viral replicative capacity. Structural analysis reveals that T242 plays a critical role in defining the start point and in stabilizing helix 6 within p24 Gag, ensuring that escape occurs at a significant cost. A very similar role is played by Thr-180, which is also an escape residue, but within a second p24 Gag epitope associated with immune control. Analysis of HIV type 1 gag in 206 B*57/5801-positive subjects reveals three principle alternative TW10-associated variants, and each is strongly linked to concomitant additional variants within p24 Gag, suggesting that functional constraints operate against their occurrence alone. The extreme conservation of p24 Gag and the predictable nature of escape variation resulting from these tight functional constraints indicate that p24 Gag may be a critical immunogen in vaccine design and suggest novel vaccination strategies to limit viral escape options from such epitopes.

24 December 2009 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
JFJacques Fellay
Jacques Fellay
DGDongliang Ge
Dongliang Ge
KSKevin V Shianna
Kevin V Shianna
SCSara Colombo
Sara Colombo
BLBruno Ledergerber
Bruno Ledergerber
N(Niaid Center For Hiv/Aids Vaccine Immunology (Chavi)
Niaid Center For Hiv/Aids Vaccine Immunology (Chavi)
To extend the understanding of host genetic determinants of HIV-1 control, we performed a genome-wide association study in a cohort of 2,554 infected Caucasian subjects. The study was powered to detect common genetic variants explaining down to 1.3% of the variability in viral load at set point. We provide overwhelming confirmation of three associations previously reported in a genome-wide study and show further independent effects of both common and rare variants in the Major Histocompatibility Complex region (MHC). We also examined the polymorphisms reported in previous candidate gene studies and fail to support a role for any variant outside of the MHC or the chemokine receptor cluster on chromosome 3. In addition, we evaluated functional variants, copy-number polymorphisms, epistatic interactions, and biological pathways. This study thus represents a comprehensive assessment of common human genetic variation in HIV-1 control in Caucasians. The ability to spontaneously control HIV-1 upon infection is highly variable between individuals. To evaluate the contribution of variation in human genes to differences in plasma viral load and in disease progression rates, we performed a genome-wide association study in >2,500 HIV–infected individuals. This study achieved two goals: it completed the analysis of common variation influencing viral control, and it re-assessed the majority of previously reported genetic associations. We show that genetic variants located near the HLA-B and HLA-C genes are the strongest determinants of viral control, and that other independent associations exist in the same region of chromosome 6, the Major Histocompatibility Complex, known to contain a large number of genes involved in immune defense. We could not replicate most of the previously published associations with HIV candidate genes in this large, well-characterized cohort. Overall, common human genetic variation, together with demographic variables, explains up to 22% of the variability in viral load in the Caucasian population.